BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Synthetic Biologics, Inc. (SYN)' SYN-004 For The Prevention Of C. Difficile Infections Named a "Top Project To Watch" By Elsevier Business Intelligence


11/14/2013 11:59:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.
, Nov. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today announced that SYN-004, Synthetic Biologics' product candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in the infectious disease area. This selection was made through Elsevier Business Intelligence's panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The Company also announced that Jeffrey Riley, CEO, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19, 2013 at 4:00pm (EST) at the Hyatt Regency in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with conference attendees on Tuesday and Wednesday, November 19 and 20, 2013.

About Elsevier Business Intelligence and the Therapeutic Area Partnerships Conference

Elsevier Business Intelligence provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing a combination of news and information together with penetrating insight and analysis.

Organized by Elsevier Business Intelligence, the 2013 Therapeutic Area Partnerships (TAP) conference is designed to bring together biopharmaceutical industry decision makers to assess the most promising drug programs available for partnering in the following therapeutic areas: oncology, cardiovascular/metabolic diseases, neuroscience, infectious diseases, anti-inflammatory/autoimmune diseases and advanced therapies. For more information, please visit the conference website at http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.

About Synthetic Biologics, Inc.

Synthetic Biologics (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.

SOURCE Synthetic Biologics, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES